TargeGen initiates Phase II clinical trial of topically-applied drug for age-related macular degeneration
News | 07. 30. 2007
TargeGen, Inc. today announced that the Company has initiated a multi-center Phase II clinical trial of topically applied TG100801 in patients with age-related macular degeneration (AMD).
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.
© 2018 Pappas Capital, LLC. ALL RIGHTS RESERVED.